Literature DB >> 16924379

Validated HPLC-MS-MS method for simultaneous determination of atorvastatin and 2-hydroxyatorvastatin in human plasma-pharmacokinetic study.

V Borek-Dohalský1, J Huclová, B Barrett, B Nemec, I Ulc, I Jelínek.   

Abstract

Cholesterol-reducing statin drugs are the most frequently prescribed agents for reducing morbidity and mortality related to coronary heart disease. In this publication a validated, highly sensitive, and selective isocratic HPLC method is reported for quantitative determination of the major statin drug atorvastatin (ATV) and its metabolite 2-hydroxyatorvastatin (HATV). Detection was performed with an electrospray ionization triple-quadrupole mass spectrometer equipped with an ESI interface operating in positive-ionization mode. Multiple reaction monitoring (MRM) was used for MS-MS detection. The calibration plot was linear in the concentration range 0.10-40.00 ng mL(-1) for both ATV and HATV. Inter-day and intra-day precision and accuracy of the proposed method were characterized by measurement of relative standard deviation (RSD) and percentage deviation, respectively; both were less than 8% for both analytes. The limit of quantitation was 0.02 ng mL(-1) for ATV and 0.07 ng mL(-1) for HATV. The method was used for pharmacokinetic study of ATV and HATV. Pharmacokinetic data for all analytes are also reported.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16924379     DOI: 10.1007/s00216-006-0655-3

Source DB:  PubMed          Journal:  Anal Bioanal Chem        ISSN: 1618-2642            Impact factor:   4.142


  15 in total

1.  Atorvastatin is 10-fold more active in vitro than other statins against Plasmodium falciparum.

Authors:  Bruno Pradines; Marylin Torrentino-Madamet; Albin Fontaine; Maud Henry; Eric Baret; Joel Mosnier; Sébastien Briolant; Thierry Fusai; Christophe Rogier
Journal:  Antimicrob Agents Chemother       Date:  2007-05-14       Impact factor: 5.191

2.  Statins as potential antimalarial drugs: low relative potency and lack of synergy with conventional antimalarial drugs.

Authors:  Rina P M Wong; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2009-03-02       Impact factor: 5.191

3.  Atorvastatin as a potential antimalarial drug: in vitro synergy in combinational therapy with dihydroartemisinin.

Authors:  Hélène Savini; Jean Baptiste Souraud; Sébastien Briolant; Eric Baret; Rémy Amalvict; Christophe Rogier; Bruno Pradines
Journal:  Antimicrob Agents Chemother       Date:  2009-11-30       Impact factor: 5.191

4.  High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial.

Authors:  Anuradha Ganesan; Nancy Crum-Cianflone; Jeanette Higgins; Jing Qin; Catherine Rehm; Julia Metcalf; Carolyn Brandt; Jean Vita; Catherine F Decker; Peter Sklar; Mary Bavaro; Sybil Tasker; Dean Follmann; Frank Maldarelli
Journal:  J Infect Dis       Date:  2011-02-15       Impact factor: 5.226

5.  Atorvastatin as a potential anti-malarial drug: in vitro synergy in combinational therapy with quinine against Plasmodium falciparum.

Authors:  Véronique Parquet; Maud Henry; Nathalie Wurtz; Jerome Dormoi; Sébastien Briolant; Marine Gil; Eric Baret; Rémy Amalvict; Christophe Rogier; Bruno Pradines
Journal:  Malar J       Date:  2010-05-25       Impact factor: 2.979

6.  Atorvastatin treatment is effective when used in combination with mefloquine in an experimental cerebral malaria murine model.

Authors:  Jean-Baptiste Souraud; Sébastien Briolant; Jérome Dormoi; Joel Mosnier; Hélène Savini; Eric Baret; Rémy Amalvict; Raoulin Soulard; Christophe Rogier; Bruno Pradines
Journal:  Malar J       Date:  2012-01-10       Impact factor: 2.979

7.  Impact of methylene blue and atorvastatin combination therapy on the apparition of cerebral malaria in a murine model.

Authors:  Jérome Dormoi; Sébastien Briolant; Camille Desgrouas; Bruno Pradines
Journal:  Malar J       Date:  2013-04-15       Impact factor: 2.979

8.  Simultaneous Determination of Atorvastatin and Aspirin in Human Plasma by LC-MS/MS: Its Pharmacokinetic Application.

Authors:  Ramakrishna Gajula; Nageswara Rao Pilli; Vasu Babu Ravi; Rambabu Maddela; Jaswanth Kumar Inamadugu; Srinivasa Rao Polagani; Sobha Busa
Journal:  Sci Pharm       Date:  2012-08-06

9.  Stress Degradation Behavior of Atorvastatin Calcium and Development of a Suitable Stability-Indicating LC Method for the Determination of Atorvastatin, its Related Impurities, and its Degradation Products.

Authors:  Pallavi Vukkum; J Moses Babu; R Muralikrishna
Journal:  Sci Pharm       Date:  2012-10-09

10.  Improvement of the efficacy of dihydroartemisinin with atorvastatin in an experimental cerebral malaria murine model.

Authors:  Jérôme Dormoi; Sébastien Briolant; Aurélie Pascual; Camille Desgrouas; Christelle Travaillé; Bruno Pradines
Journal:  Malar J       Date:  2013-08-30       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.